Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free UNCY Stock Alerts

Unicycive Therapeutics (UNCY) Competitors

Unicycive Therapeutics logo
$5.16 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern
Compare

UNCY vs. OVID, RLMD, CGC, BIOA, and AVIR

Should you buy Unicycive Therapeutics stock or one of its competitors? Unicycive Therapeutics's main competitors and comparable companies include Ovid Therapeutics (OVID), Relmada Therapeutics (RLMD), Canopy Growth (CGC), BioAge Labs (BIOA), and Atea Pharmaceuticals (AVIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Unicycive Therapeutics compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Unicycive Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -23.64% beat Unicycive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ovid Therapeutics-240.11% -23.64% -20.52%
Unicycive Therapeutics N/A -91.50%-61.47%

Ovid Therapeutics currently has a consensus target price of $5.86, suggesting a potential upside of 109.18%. Unicycive Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 263.37%. Given Unicycive Therapeutics' higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Ovid Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ovid Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
Unicycive Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57

72.2% of Ovid Therapeutics shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 7.0% of Ovid Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ovid Therapeutics has higher revenue and earnings than Unicycive Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ovid Therapeutics$7.25M75.43-$17.41M-$0.31N/A
Unicycive Therapeutics$680K211.33-$26.56M-$1.75N/A

In the previous week, Unicycive Therapeutics had 12 more articles in the media than Ovid Therapeutics. MarketBeat recorded 15 mentions for Unicycive Therapeutics and 3 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 1.15 beat Unicycive Therapeutics' score of -0.02 indicating that Ovid Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ovid Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Unicycive Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

Ovid Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Summary

Ovid Therapeutics beats Unicycive Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Relmada Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Unicycive Therapeutics presently has a consensus price target of $18.75, suggesting a potential upside of 263.37%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 170.88%. Given Unicycive Therapeutics' higher probable upside, research analysts clearly believe Unicycive Therapeutics is more favorable than Relmada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Unicycive Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Unicycive Therapeutics had 10 more articles in the media than Relmada Therapeutics. MarketBeat recorded 15 mentions for Unicycive Therapeutics and 5 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.41 beat Unicycive Therapeutics' score of -0.02 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Unicycive Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Relmada Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Unicycive Therapeutics has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Unicycive Therapeutics$680K211.33-$26.56M-$1.75N/A
Relmada TherapeuticsN/AN/A-$57.38M-$0.90N/A

Relmada Therapeutics' return on equity of -47.52% beat Unicycive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Unicycive TherapeuticsN/A -91.50% -61.47%
Relmada Therapeutics N/A -47.52%-43.97%

Summary

Relmada Therapeutics beats Unicycive Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Canopy Growth?

Unicycive Therapeutics (NASDAQ:UNCY) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Unicycive Therapeutics has higher earnings, but lower revenue than Canopy Growth. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Unicycive Therapeutics$680K211.33-$26.56M-$1.75N/A
Canopy Growth$251.01M1.74-$190.29M-$0.45N/A

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Canopy Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Unicycive Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 263.37%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Canopy Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Unicycive Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Canopy Growth
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Unicycive Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Unicycive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Unicycive TherapeuticsN/A -91.50% -61.47%
Canopy Growth -65.33%-21.91%-14.34%

In the previous week, Unicycive Therapeutics had 10 more articles in the media than Canopy Growth. MarketBeat recorded 15 mentions for Unicycive Therapeutics and 5 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.83 beat Unicycive Therapeutics' score of -0.02 indicating that Canopy Growth is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Unicycive Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Canopy Growth
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Summary

Unicycive Therapeutics beats Canopy Growth on 10 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to BioAge Labs?

Unicycive Therapeutics (NASDAQ:UNCY) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Unicycive Therapeutics presently has a consensus target price of $18.75, suggesting a potential upside of 263.37%. BioAge Labs has a consensus target price of $36.57, suggesting a potential upside of 281.35%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts clearly believe BioAge Labs is more favorable than Unicycive Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Unicycive Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
BioAge Labs
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71

Unicycive Therapeutics has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Unicycive Therapeutics$680K211.33-$26.56M-$1.75N/A
BioAge Labs$8.99M48.96-$80.61M-$2.38N/A

Unicycive Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Unicycive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Unicycive TherapeuticsN/A -91.50% -61.47%
BioAge Labs -912.26%-28.99%-27.09%

Unicycive Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

40.4% of Unicycive Therapeutics shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 17.6% of BioAge Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 7 more articles in the media than BioAge Labs. MarketBeat recorded 15 mentions for Unicycive Therapeutics and 8 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 1.27 beat Unicycive Therapeutics' score of -0.02 indicating that BioAge Labs is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Unicycive Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
BioAge Labs
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Unicycive Therapeutics and BioAge Labs tied by winning 8 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Atea Pharmaceuticals?

Unicycive Therapeutics (NASDAQ:UNCY) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

In the previous week, Unicycive Therapeutics had 13 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 15 mentions for Unicycive Therapeutics and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.70 beat Unicycive Therapeutics' score of -0.02 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Unicycive Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Atea Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Unicycive Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 263.37%. Atea Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 20.07%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Unicycive Therapeutics is more favorable than Atea Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Unicycive Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Atea Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

Unicycive Therapeutics has higher revenue and earnings than Atea Pharmaceuticals. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Unicycive Therapeutics$680K211.33-$26.56M-$1.75N/A
Atea PharmaceuticalsN/AN/A-$158.35M-$2.08N/A

Atea Pharmaceuticals' return on equity of -64.25% beat Unicycive Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Unicycive TherapeuticsN/A -91.50% -61.47%
Atea Pharmaceuticals N/A -64.25%-57.12%

Summary

Unicycive Therapeutics beats Atea Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Unicycive Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UNCY vs. The Competition

Export
MetricUnicycive TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$143.71M$12.19B$7.21B$12.89B
Dividend YieldN/A2.59%2.54%9.13%
P/E Ratio-2.95792.20273.8425.45
Price / Sales211.33760.84625.55100.83
Price / CashN/A15.1828.9235.62
Price / Book3.6611.0911.016.39
Net Income-$26.56M$2.83B$3.49B$358.69M
7 Day Performance-0.77%4.42%1.63%0.22%
1 Month Performance1.78%6.88%4.42%-0.10%
1 Year Performance18.35%10.00%24.21%14.04%

Unicycive Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UNCY
Unicycive Therapeutics
2.5237 of 5 stars		$5.16
flat		$18.75
+263.4%		+18.3%$143.73M$680KN/A9
OVID
Ovid Therapeutics
2.1837 of 5 stars		$2.73
+2.1%		$5.71
+109.7%		+127.6%$532.58M$7.25MN/A60
RLMD
Relmada Therapeutics
2.2584 of 5 stars		$4.44
+1.7%		$12.00
+170.6%		+168.5%$473.08MN/AN/A10
CGC
Canopy Growth
1.0466 of 5 stars		$0.98
-1.2%		N/A-33.4%$441.21M$251.01MN/A1,128
BIOA
BioAge Labs
3.7328 of 5 stars		$9.56
+0.6%		$36.57
+282.5%		+101.5%$438.80M$8.99MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:UNCY) was last updated on 9/7/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel